This company seems to have been delisted
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
KemPharm
KMPH
S$7.48
Share price
-0.34%
Change (1 day)
2.29%
Change (1 year)
Categories
Revenue for KemPharm (KMPH)
Revenue in 2022 (TTM): S$14.41 Million
According to KemPharm's latest financial reports the company's current revenue (TTM 
) is S$13.46 Million. In 2021 the company made a revenue of S$38.73 Million an increase over the revenue in the year 2020 that were of S$17.57 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for KemPharm from 2014 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | S$14.41 M | -62.79% |
| 2021 | S$38.73 M | 120.33% |
| 2020 | S$17.57 M | 1.56% |
| 2019 | S$17.3 M | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Jazz Pharmaceuticals JAZZ | S$5.23 B | 38,767.93% | 🇮🇪 Ireland |
 Agile Therapeutics
AGRX | S$27.76 M | 106.23% | 🇺🇸 USA |
 Theravance Biopharma
TBPH | S$84.03 M | 524.08% | Cayman Islands |
 ANI Pharmaceuticals ANIP | S$0.86 B | 6,345.48% | 🇺🇸 USA |